United States - English - NLM (National Library of Medicine)

a-s medication solutions - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - triumeq is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and in pediatric patients weighing at least 40 kg. limitations of use: triumeq is contraindicated in patients:   pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to triumeq during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1‑800‑258‑4263. risk summary preliminary data from an observational study has identified a possible increased risk of neural tube defects when dolutegravir, a component of triumeq, is administered at the time of conception compared with non-dolutegravir-containing antiretroviral regimens. as defects related to closure of the neural tube occur from conception through the first 6 weeks of gestation, embryos exposed to dolutegravir from the time of conception through the first 6 weeks of gestation are at potential risk. in addition, 2